With syndicate investing $132M, Jasper merging with Kira: Deals Report

A merger and concurrent private placement will bring products from Kira and Jasper under the same roof, with $132 million in fresh cash driving development of assets for hematology and immunology.

On Thursday, Jasper Pharmaceuticals Inc. (NASDAQ:JSPR) and Kira Pharmaceuticals LLC said they had completed a merger, about six weeks after Jasper said it would explore strategic alternatives. The deal isn’t a reverse merger, strictly speaking; two of the three programs it has prioritized come from Kira, and one from Jasper, though it will retain the Jasper name. The combined organization’s CEO, Jeet Mahal, and CFO, Herb Cross, are also coming from Jasper’s side, and will remain in their roles...